• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Aeterna Zentaris Inc. - Common Stock
Atlantic Power & Infrastructure Corp
Aurora Spine Corp
BranchOut Food Inc. - Common Stock
Computershare Ltd AUD
Eastside Distilling, Inc. - Common Stock
Elektros Inc
Fast Retailing CO Ltd
Ideal Power Inc. - Common Stock
Panbela Therapeutics, Inc. - Common Stock
Pasqal Holding SA - Warrant
Shimizu Corp
SpringBig Holdings, Inc. - Common Stock
Xos, Inc. - Common Stock
Yunji Inc. - American Depository Shares
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

3.620 -0.110 (-2.95%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,751,862
Open 3.730
Bid (Size) 3.590 (200)
Ask (Size) 3.750 (300)
Prev. Close 3.730
Today's Range 3.600 - 3.745
52wk Range 3.455 - 7.300
Shares Outstanding 64,465,037
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
October 01, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire

Performance

52-Week Range 50.4% below 52-week high
3.620
3.4652W Low 7.3052W High
1 Week 20.6% below 1-week high
3.461W Low 4.561W High

Taysha Gene Therapies, Inc. - Common Stock (TSHA) traded between $3.46 and $7.30 over the past 52 weeks and last traded at $3.62, 50.4% below its 52-week high. Over the past week it ranged between $3.46 and $4.56.

Past 12 Months
-12.6%
-28.6%
-39.3%
-43.7%
-31.0%
-28.7%
1W -$0.52
1M -$1.45
3M -$2.34
6M -$2.81
YTD -$1.63
1Y -$1.46

TSHA was -28.7% over the past year, -43.7% over six months, -31.0% year to date, -12.6% in the last week.

12 Months vs Market
TSHA
-28.7%
DIA
+13.0%
SPY
+15.5%
QQQ
+18.3%
IWM
+10.4%

Over the past 12 months TSHA returned -28.7% versus DIA (Dow) +13.0%, SPY (S&P 500) +15.5%, QQQ (Nasdaq 100) +18.3% and IWM (Russell 2000) +10.4%.

Volume & Liquidity 0.82× 3-mo avg
Today 2,751,862 3-mo avg 3.3M
1W
4.4M
1M
4.7M
3M
3.3M
6M
3.2M
YTD
3.1M
1Y
3.2M

TSHA most recently traded 2,751,862 shares against a 3-month average daily volume of 3.3M.

More News

Read More
News headline image
These 3 Risky Stocks Could Be Sitting on 100% Upside ↗
September 07, 2026
Via MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Reports Q1 2026 Miss, Reaffirms FDA Alignment on TSHA-102 Approval Path ↗
May 06, 2026
Via Chartmill
News headline image
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call ↗
August 18, 2026
Via The Motley Fool
News headline image
Taysha Gene Therapies Q2 Earnings Call Highlights ↗
August 11, 2026
Via MarketBeat
Topics Earnings
News headline image
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 07, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
August 04, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
August 03, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run ↗
July 12, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
June 25, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
June 24, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 24, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
June 22, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha (TSHA) Q1 2026 Earnings Transcript ↗
May 07, 2026
Via The Motley Fool
News headline image
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 06, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
April 29, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
April 27, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
April 02, 2026
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗
March 22, 2026
Via The Motley Fool
News headline image
Taysha (TSHA) Q4 2025 Earnings Call Transcript ↗
March 19, 2026
Via The Motley Fool
Topics Earnings

Frequently Asked Questions

Is Taysha Gene Therapies, Inc. - Common Stock publicly traded?
Yes, Taysha Gene Therapies, Inc. - Common Stock is publicly traded.
What exchange does Taysha Gene Therapies, Inc. - Common Stock trade on?
Taysha Gene Therapies, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Taysha Gene Therapies, Inc. - Common Stock?
The ticker symbol for Taysha Gene Therapies, Inc. - Common Stock is TSHA on the Nasdaq Stock Market
What is the current price of Taysha Gene Therapies, Inc. - Common Stock?
The current price of Taysha Gene Therapies, Inc. - Common Stock is 3.620
When was Taysha Gene Therapies, Inc. - Common Stock last traded?
The last trade of Taysha Gene Therapies, Inc. - Common Stock was at 10/16/26 04:00 PM ET
What is the market capitalization of Taysha Gene Therapies, Inc. - Common Stock?
The market capitalization of Taysha Gene Therapies, Inc. - Common Stock is 233.36M
How many shares of Taysha Gene Therapies, Inc. - Common Stock are outstanding?
Taysha Gene Therapies, Inc. - Common Stock has 233M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap